[8-K] Boston Scientific Corp. Reports Material Event

Rhea-AI Filing Summary

Boston Scientific Corporation announced that Jeffrey B. Mirviss, Executive Vice President and President, Peripheral Interventions, will retire effective December 1, 2025 and remain as a senior advisor through February 27, 2026. During the advisory period he will receive his current base salary of $705,000, prorated to the Retirement Date. The company expects to enter a Retirement Agreement providing payments and benefits materially consistent with its Executive Retirement Plan, 2025 Annual Bonus Plan and Long-Term Incentive Program and related equity awards.

Positive

• Planned transition with advisory overlap through February 27, 2026 supports continuity
• Retirement package aligns with existing executive plans, reducing risk of bespoke costly arrangements
• Base salary maintained at $705,000 and prorated during advisory period

Negative

• Potential short-term leadership gap if a successor is not named before December 1, 2025
• Near-term compensation expense from prorated salary and continued benefits during advisory period

Insights

Corporate Governance Analyst

Senior leadership transition is orderly with a short advisory overlap.

The announced retirement sets a clear timeline: active role until December 1, 2025 with advisory support through February 27, 2026, which reduces near-term operational disruption in Peripheral Interventions. The company commits to a standard retirement agreement tied to existing executive plans rather than bespoke severance terms.

This arrangement preserves institutional knowledge during handover but will modestly increase near-term compensation expense, specifically the prorated $705,000 base pay and continuation of benefit frameworks; monitor successor appointment timing and any disclosed transitional responsibilities over the next three months.

0000885725false00008857252025-08-292025-08-290000885725us-gaap:CommonStockMember2025-08-292025-08-290000885725bsx:SeniorNotedue2027Member2025-08-292025-08-29

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_____________________________________________________________________

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

_____________________________________________________________________

Date of Report (Date of earliest event reported): August 29, 2025

BOSTON SCIENTIFIC CORPORATION

(Exact name of registrant as specified in its charter)

Delaware

1-11083

04-2695240

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

    300 Boston Scientific Way, Marlborough, Massachusetts                 01752-1234

    (Address of principal executive offices)                           (Zip Code)

(508) 683-4000

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐			Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol

Name of each exchange on which registered

Common Stock, $0.01 par value per share

BSX

New York Stock Exchange

0.625% Senior Notes due 2027

BSX27

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company   ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;

Compensatory Arrangements of Certain Officers.

On August 29, 2025, Jeffrey B. Mirviss informed Boston Scientific Corporation (the “Company”) that he has decided to retire from his role as Executive Vice President and President, Peripheral Interventions effective as of December 1, 2025.

Mr. Mirviss is expected to remain with the Company as a senior advisor from such time through February 27, 2026 (such date, or any earlier date, the “Retirement Date”). As a senior advisor, Mr. Mirviss will receive a base salary at his current annual base salary of $705,000, prorated through the Retirement Date.

The Company expects to enter into a Retirement Agreement with Mr. Mirviss effective as of the Retirement Date, pursuant to which Mr. Mirviss will be entitled to payments and benefits that are materially consistent with those Mr. Mirviss is entitled to under, and subject to the terms and conditions of, the Company’s Executive Retirement Plan, 2025 Annual Bonus Plan and Long-Term Incentive Program and equity awards granted thereunder, respectively, each as previously filed with the U.S. Securities and Exchange Commission.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:			September 4, 2025			BOSTON SCIENTIFIC CORPORATION
						By:			/s/ Susan Thompson
									Susan Thompson
									Vice President, Chief Corporate Counsel and Assistant Secretary

FAQ

What did Boston Scientific (BSX) announce about Jeffrey B. Mirviss?

The company announced Mr. Mirviss will retire as EVP and President, Peripheral Interventions effective December 1, 2025 and serve as senior advisor through February 27, 2026.

How much will Jeffrey Mirviss be paid during the advisory period?

He will receive his current base salary of $705,000, prorated through the Retirement Date.

Will Mirviss receive additional retirement benefits?

The company expects a Retirement Agreement providing payments and benefits materially consistent with the Executive Retirement Plan, 2025 Annual Bonus Plan, and Long-Term Incentive Program.

Is the retirement immediate or will there be a handover?

The retirement is effective December 1, 2025, but Mr. Mirviss will remain as a senior advisor through February 27, 2026 to support transition.

Does the filing disclose a successor for the role?

No; the filing does not name a successor or provide timing for a replacement.